IP Library Granted Patent US 8,404,656
Granted Patent B2
US 8,404,656 · App. 12/672,869 · Granted Mar 26, 2013

Methods of treatment and prevention of diet-induced obesity and sequelae thereof

Inventors: Christopher L. Karp (Cincinnati, OH); Stuart P. Weisberg (New York, NY); Senad Divanovic (Cincinnati, OH)
Assignee: Children's Hospital Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,656
App. No.
12/672,869
Granted
Mar 26, 2013
Kind
B2
Abstract

Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopepude ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound.

Claims (1)

1. A method of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject, the method comprising administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP105 expression and/or MD-1 expression, wherein the at least one inhibitor of RP105 and/or MD-1 expression is at least one shRNA or siRNA, or a precursor thereof, and wherein the at least one precursor comprises a sequence selected from the group consisting of CCTCTTGGTCTCCAGAGTCAGGCATTCAA (SEQ ID NO: 1); CTACCTCAATCTGGCTGCCAACAGCATTA (SEQ ID NO: 2); CATCAACCTAAGCCTGAACTTCAATGGCA (SEQ ID NO: 3); and GCAGGAACACCGCTTCTCTGACATCTCAT (SEQ ID NO: 4).

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 20, 2011
From: CHILDREN'S HOSPITAL MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026154/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2011
From: KARP, CHRISTOPHER L.; WEISBERG, STUART P.; DIVANOVIC, SENAD
To: CHILDREN'S HOSPITAL MEDICAL CENTER
Reel/Frame 026031/0471 →
Continuity (2)
Provisional Application 60964084 · Aug 9, 2007
Related Publication 20110200580A1 · Aug 18, 2011